Sammy Farah, Turnstone Biologics CEO
July 28, 2022 09:50 AM EDTUpdated 03:20 PM
Pharma

Take­da ax­es clin­i­cal-stage pro­gram in $1B+ Turn­stone Bi­o­log­ics col­lab­o­ra­tion

Kyle LaHucik

Senior Reporter

Take­da has end­ed its work with Turn­stone Bi­o­log­ics on a sol­id tu­mor as­set that was in a Phase I/IIa study, up­end­ing a 2019 deal that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times